Exencial Wealth Advisors LLC Has $1.71 Million Stock Position in Novo Nordisk A/S $NVO

Exencial Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 5.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,822 shares of the company’s stock after purchasing an additional 1,221 shares during the period. Exencial Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,713,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. First Hawaiian Bank boosted its position in Novo Nordisk A/S by 0.6% during the first quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock valued at $1,556,000 after purchasing an additional 142 shares during the last quarter. Anchor Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.1% in the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock worth $944,000 after buying an additional 150 shares during the last quarter. Xponance Inc. lifted its position in shares of Novo Nordisk A/S by 5.0% in the first quarter. Xponance Inc. now owns 3,314 shares of the company’s stock worth $230,000 after buying an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC lifted its position in shares of Novo Nordisk A/S by 3.8% in the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock worth $319,000 after buying an additional 166 shares during the last quarter. Finally, Werba Rubin Papier Wealth Management lifted its position in shares of Novo Nordisk A/S by 4.1% in the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after buying an additional 173 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Finally, HSBC set a $70.00 price objective on Novo Nordisk A/S in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $76.00.

Novo Nordisk A/S Trading Down 2.6%

Shares of NVO opened at $53.37 on Thursday. The stock’s 50-day moving average price is $56.51 and its 200 day moving average price is $62.52. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $238.29 billion, a price-to-earnings ratio of 14.66, a P/E/G ratio of 2.49 and a beta of 0.68. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $116.43.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.